Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5m per year in England (or £9,100 per 100,000 population). This is because the technology is an option alongside current standard treatment options, the drugs are similarly priced and we do not think practice will change substantially as a result of this guidance.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: 12 July 2017